SOURCE: TheraBiogen, Inc.

May 17, 2011 09:39 ET

TheraBiogen, Inc. Provides Corporate Update

NEW YORK, NY--(Marketwire - May 17, 2011) - TheraBiogen, Inc. (OTCQB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms made from natural homeopathic ingredients, provides the following Summary of Information regarding its activities:

  • Launched national sales and distribution program with Rite-Aid that has resulted in follow-up orders;
  • Executed sponsorship agreement with Miami HEAT;
    • Partnership includes product placement on local radio and local and national TV;
  • Featured in an analyst report from national independent institutional equity research firm, Mithra Research, Inc. (;
  • Added sales and distribution in Walgreens Miami District South, Hannaford Supermarkets, Discount Drug Mart, and Big Y Supermarkets;
  • Signed licensing agreement with DelRx Pharmaceutical Corp. to provide for oral delivery of its Thera Max formulation;
  • Engaged Melwood Partners as marketing agent for national launch of Thera Maxproducts;
  • Continue to pursue discussions with other national pharmaceutical and general retailers for distribution of Thera Maxfor the Fall 2011 cold and flu season;
  • Launched social media strategy with initial Facebook page. See

Thera Max is available for sale in thousands of locations from Rite-Aid, Walgreens Miami South District, Hannaford Supermarket, Discount Drug Mart and Big Y Supermarkets. For more information on Thera Max visit our website or our Facebook page at

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

Contact Information

  • Company Contact:
    TheraBiogen, Inc.
    Kelly T. Hickel
    Chairman and CEO
    Email Contact